These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38384303)

  • 21. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential gene expression elicited by children in response to the 2015-16 live attenuated versus inactivated influenza vaccine.
    Cole KS; Martin JM; Horne WT; Lin CJ; Nowalk MP; Alcorn JF; Zimmerman RK
    Vaccine; 2017 Dec; 35(49 Pt B):6893-6897. PubMed ID: 29132989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults.
    Tawfik A; Kawaguchi T; Takahashi M; Setoh K; Yamaguchi I; Tabara Y; Van Steen K; Sakuntabhai A; Matsuda F
    Expert Rev Vaccines; 2023; 22(1):826-838. PubMed ID: 37747798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection.
    Ochsner SP; Li W; Rajendrakumar AM; Palaniyandi S; Acharya G; Liu X; Wang G; Krammer F; Shi M; Tuo W; Pauza CD; Zhu X
    J Immunol; 2021 Sep; 207(5):1310-1321. PubMed ID: 34380652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmablast-derived polyclonal antibody response after influenza vaccination.
    He XS; Sasaki S; Narvaez CF; Zhang C; Liu H; Woo JC; Kemble GW; Dekker CL; Davis MM; Greenberg HB
    J Immunol Methods; 2011 Feb; 365(1-2):67-75. PubMed ID: 21182843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.
    Haralambieva IH; Painter SD; Kennedy RB; Ovsyannikova IG; Lambert ND; Goergen KM; Oberg AL; Poland GA
    PLoS One; 2015; 10(3):e0122282. PubMed ID: 25816015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza vaccines: a moving interdisciplinary field.
    Schotsaert M; García-Sastre A
    Viruses; 2014 Oct; 6(10):3809-26. PubMed ID: 25302957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine.
    Sun Y; Bian C; Xu K; Hu W; Wang T; Cui J; Wu H; Ling Z; Ji Y; Lin G; Tian L; Zhou Y; Li B; Hu G; Yu N; An W; Pan R; Zhou P; Leng Q; Huang Z; Ma X; Sun B
    PLoS One; 2010 Dec; 5(12):e14270. PubMed ID: 21151563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
    Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
    J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breadth of Antibody Responses during Influenza Virus Infection and Vaccination.
    Kubo M; Miyauchi K
    Trends Immunol; 2020 May; 41(5):394-405. PubMed ID: 32265127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.
    Henry C; Palm AE; Utset HA; Huang M; Ho IY; Zheng NY; Fitzgerald T; Neu KE; Chen YQ; Krammer F; Treanor JJ; Sant AJ; Topham DJ; Wilson PC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31434733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.
    Gao J; Klenow L; Parsons L; Malik T; Phue JN; Gao Z; Withers SG; Cipollo J; Daniels R; Wan H
    J Virol; 2021 Nov; 95(24):e0116021. PubMed ID: 34613807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.